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ABSTRACT
Objectives: Phenylketonuria (PKU) was the first inherited metabolic disease known to cause mental 
retardation for which a newborn screening program (NBS) was developed. The objective of this study 
was to evaluate the effectiveness of PKU NBS and the management of cases in the northeastern Bra-
zilian state of Sergipe (SE). Materials and methods: We reviewed the phenylalanine concentrations 
in filter-paper collected from the heel (PKUneo) of 43,449 newborns; blood concentrations obtained 
by venipuncture in the subjects with abnormal PKUneo; the children’s age at several phases of the 
program, the incidence of the disease from January 2007 to June 2008; and metabolic control of the 
patients. Results: The coverage of NBS/SE was 78.93%. The children’s age was 10 ± 7 days at PKUneo 
collection. Twelve children were recalled based on the PKUneo cutoff value at 28 ± 13 days. From the-
se, the concentrations of phenylalanine collected by venipuncture were normal in five children. The 
incidence of hyperphenylalaninemia was 1/43,449, and of PKU was 1/8,690 (5 cases). One suspected 
subject died. Another death occurred in the cohort, in a confirmed PKU case. PKU treatment began 
within 51 ± 12 days of life. In the four patients under dietary phenylalanine restriction, metabolic 
control was often difficult. Conclusions: PKU NBS/SE has satisfactory coverage and adequate cutoff 
for recalling patients and diagnosis, but the onset of treatment is delayed, and follow-up metabolic 
control is frequently inadequate. Arq Bras Endocrinol Metab. 2014;58(1):62-7
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RESUMO
Objetivos: A fenilcetonúria (PKU) foi a primeira causa metabólica hereditária de retardamento men-
tal para a qual foi desenvolvido um programa de triagem em recém-nascidos (NBS). O objetivo 
deste estudo foi avaliar a eficácia do NBS para a PKU e o manejo dos casos em Sergipe (SE), Brasil. 
Materiais e métodos: Revisamos as concentrações de fenilalanina no filtro de papel coletado do 
calcanhar (PKUneo) de 43.449 recém-nascidos, suas concentrações de sangue obtidas por punção 
venosa em indivíduos com PKUneo anormal, a idade das crianças em diversas fases do programa, 
a incidência da doença no período de janeiro de 2007 a junho de 2008 e o controle metabólico dos 
pacientes. Resultados: A cobertura da NBS/SE foi de 78,93%. A idade das crianças era de 10 ± 7 dias 
na coleta de PKUneo. Doze crianças foram reconvocadas com base no ponto de corte de PKUneo aos 
28 ± 13 dias de idade. Destas, as concentrações de fenilalanina por venipunctura foram normais em 
cinco. A incidência da hiperfenilalaninemia foi 1/43.449 e de PKU foi 1/8.690 (5 casos), e um indivíduo 
suspeito foi a óbito. Outro óbito ocorreu na coorte em um caso de PKU confirmado. O tratamento 
para a PKU começou com 51 ± 12 dias. Nos quatro pacientes sob restrição de fenilalanina alimentar, 
o controle metabólico foi frequentemente difícil. Conclusões: PKU NBS/SE apresenta uma cober-
tura satisfatória e ponto de corte adequado para reconvocação e diagnóstico, mas o início do trata-
mento é atrasado e o controle no seguimento é frequentemente inadequado. Arq Bras Endocrinol Metab. 
2014;58(1):62-7
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PKU patients. We thought that these recent data, 
obtained in Brazil Northeastern region, can be very 
valuable, especially when Brazilian NBS is expanding 
with the introduction of new diseases to be screened.
MATERIALS AND METHODS
A cross-sectional study was conducted in 43,449 
children screened by NBS/SE at the University Hospital 
of Universidade Federal de Sergipe from January 2007 
to July 2008. Immediately after collection, heel blood 
samples were placed on filter paper, and stored in a 
refrigerator at 4ºC in the local clinics in all 75 Sergipe 
municipalities. Transport from all the collection stations 
occurs daily, with samples at room temperature, to the 
University Hospital Laboratory in Aracaju. The time 
between collection and arrival to the laboratory did 
not exceed 6 hours. Phenylalanine was measured on 
filter paper (type 903 SS) by an enzymatic colorimetric 
method (Quantase/Intercientífica, Glasgow, Scotland).
The following parameters were studied: number 
and age of screened newborns phenylalanine concen-
trations in different phases of the NBS/SE; its fre-
quency distribution; PKU and hyperphenylalaninemia 
incidences; and program coverage.
The cutoff for phenylalanine in filter paper, to 
define suspected PKU children was obtained for a 95% 
confidence interval, from all the collected samples, 
according to the methodology described elsewhere 
(18-20). The result of phenylalanine in filter paper 
above the cutoff point was repeated and the average 
of duplicates was used. Hyperphenylalaninemia was 
defined a phenylalanine concentration, greater than 
5.0 mg/dL (21). Any child with level above this cutoff 
value is referred to the multiprofessional outpatient 
clinic of University Hospital for PKU confirmation. 
Venous blood was obtained and serum Phe was 
measured in duplicate by an enzymatic colorimetric 
process. Children are then classified based in venous 
Phe values (5,21-24) as follows: 
A) Children ruled out for PKU: phenylalanine less 
than or equal to 5.0 mg/dL.
B) Hyperphenylalaninemia: between 5.01 and 
10.0 mg/dL.
C) Mild phenylketonuria: between 10.01 and 20.0 
mg/dL.
D) Classical phenylketonuria: greater than 20 mg/dL.
E) Unknown cases: children whose parents did not 
respond to the recall.
INTRODUCTION
P henylketonuria (PKU) is an autosomal recessive disease with an incidence in Caucasian populations 
between 1 in 10,000 and 1 in 15,000 people (1,2). 
It results from more than 500 different mutations 
in phenylalanine hydroxilase gene located on 
chromossome 12q. Mutations cause reduced activity of 
the enzyme and deficient conversion of phenylalanine 
to tyrosine. This causes an increase of phenylalanine 
(Phe) in the blood stream and body tissues, with urinary 
elimination of phenylpiruvic acid and variable capacity 
of metabolism of dietary Phe. For decades, early 
screening and lifetime use of low Phe diet have been 
recommended to avoid cerebral damage resulting in 
mental deficit, and motor, neurological, and behavioral 
problems. Despite this, cognitive performance is still 
suboptimal in most series (1,3-9), and studies with 
magnetic resonance imaging have shown white matter 
lesions in the brain of adult PKU patients, which are 
directly related with blood Phe concentration (10-12).
The introduction of newborn screening programs 
(NBS) represents an important instrument in the 
secondary prevention of neurological damage caused 
by PKU.  The screening programs must be evaluated 
systematically,  and the results of this evaluation can 
modify the routine of the service and affect public care 
management (13,14).  The present Brazilian Health 
Ministry NS policy implemented in 2001 established 
the University Hospital of the Universidade Federal 
de Sergipe as the unique center allowed to perform 
neonatal screening in the State of Sergipe (SE), which 
is mandatory in the public health care system. Private 
NBS is not included in governmental statistics of 
NBS, as this information is not mandatory. SE is the 
smallest state of Brazil, with the highest gross domestic 
product of the Northeastern states. We have previously 
demonstrated that NBS for congenital hypothyroidism 
in the State of SE had an almost universal coverage, 
and resulted in an improvement in the time of onset 
of therapy. Despite of this, we found the need for 
reducing thyroid stimulating hormone (TSH) cutoff 
levels to recall suspect cases with less severe cases of 
congenital hypothyroidism, in order to achieve a full 
cerebral function (15-17). We do not know if the cutoff 
levels to recall PKU suspects also needs to change, and 
if coverage, incidence, and the follow-up of patients 
with low phenylalanine diet are appropriate. 
The aim of this paper is to evaluate both the NBS/
SE for PKU and the dietary care of our followed-up 
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Monitoring of detected cases was carried out by 
checking medical records of venous phenylalanine levels 
over time, the child weight, and daily dietary ingestion 
of phenylalanine. Metabolic control was defined normal 
when serum Phe is from 2 to 6 mg/dL (22).
Student t test was used to compare the cutoffs values 
of screened children aged 2 to 6 days, and the total of 
screened children groups. A linear regression model 
was used to compare the cutoff values of various ages, 
in the day of collection, from 2 to 30 days. Values of p 
less than 0.05 were considered significant. The research 
was approved by the Research Ethics Committee of the 
Universidade Federal de Sergipe.
RESULTS 
NBS/SE coverage was 78.93% in 2007. The incidence 
of hyperphenylalaninemia was 1/43,449. The incidence 
of PKU was 1/8,690. There was one case of mild PKU 
(20% of the cases) and four cases of classic PKU (80% 
of the cases). There was one unresolved case, due to 
the death of the child before the recall (8.33%). The 
highest percentage (32.36%) of the screened children 
had phenylalaninemia levels ranging between 1.01 to 
1.50 mg/dL. The cumulative frequency below 5 mg/
dL was 99.97% and, therefore, the recall rate was 0.03% 
of all screened children. Table 1 shows the frequency 
distribution for phenylalanine intervals concentration 
collected in filter paper, and the selected cases above 
the cutoff value with diagnosis after venous blood 
measurement.
The mean age of screened children was 9.96 ± 7.23 
days at the time of filter paper collection; 27.93 ± 13.08 
days at the time of filter paper assay; and 52.82 ± 16.95 
days for venous blood collection. The age at the filter 
paper collection in the PKU cases was 9.80 ± 8.32 days, 
with mean PKUneo concentration of 17.37 ± 9.16 
mg/dL and mean venous phenylalanine concentration 
of 24.02 ± 7.26 mg/dL. PKU treatment began within 
51 ± 12 days of life. Of the 12 PKU suspected cases, 
four (33.33%) had PKUneo greater than 10 mg/dL 
and venous phenylalanine concentration higher than 
10 mg/dL. Of 8 cases with PKUneo less than or equal 
to 10 mg/dL, one child with PKUneo of 5.73 mg/dL 
had PKU with venous phenylalanine of 20.20 mg/dL. 
There was one death of a child with PKU confirmed at 
90 days of life (age at collection on filter paper: 24 days, 
PKUneo 16.74 mg/dL, venous phenylalanine 13.30 
Table 1. Frequency distribution of phenylalanine filter paper concentration in children of NBS/SE, from January 2007 to June 2008, with the selected 
cases above the cutoff value and diagnosis after venous measurement
PKUneo mg/dL n % %A Selection PKUrecall Discarded Hyperphenyl Phenylketonunia Unknown
0.01 - 5.00 43,437 99,972 99,972 - - - - - -
5.73 1 0.002 99,974 1 20.20 0 0 1 0
5.93 1 0.002 99,977 1 - 0 0 0 1 death
6.51 1 0.002 99,979 1 1.80 1 0 0 0
6.58 1 0.002 99,981 1 2.40 1 0 0 0
6.76 1 0.002 99,984 1 1.85 1 0 0 0
6.83 1 0.002 99,986 1 3.05 1 0 0 0
8.10 1 0.002 99,988 1 8.00 0 1 0 0
9.58 1 0.002 99,990 1 2.29 1 0 0 0
12.70 1 0.002 99,993 1 31.60 0 0 1 0
16.74 1 0.002 99,995 1 13.30 0 0 1 0
21.70 1 0.002 99,997 1 26.80 0 0 1 0
30.00 1 0.002 100,000 1 28.15 0 0 1 0
Total 43,449 100,000 - 12 - 5 1 5 1
Selected % - - - 100.00 - 41.67 8.33 41.67 8.33
Prevalence - - - 3,621 - 8,690 43,449 8,690 43,449
% screened - - - 0.028 - 0.011 0.002 0.011 0.002
n: number of screened children; %: children percentage; %A: accumulated children percentage; PKUrecall: venous phenylal: concentration in the recall; PKUneo: phenylalanine concetrations in filter 
paper; Hyperphenyl: Hyperphenylalaninemia.
Confirmed PKU cases are in bold.
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mg/dL, beginning of treatment 74 days). The cause of 
death is unknown.
From the 43.449 screened children in the period, 
only 26.74% of children were the ideal age (4.76 ± 
1.04 days), between 2 and 6 days of life. There was 
no difference between PKUneo concentration values in 
children whose samples were collected between 2 to 6 
days and after 6 days (1.65 ± 0.65 mg/dL and 1.59 ± 
0.63 mg/dL, respectively). 
The biochemical control of the four patients followed 
up in 2011 was compared with the recommended 
maximal level of serum Phe (6 mg/dL) (22) and 
summarized below: 
•	 Patient code 1: 90.91% of 11 serum Phe from 125 
to 1,288 days old were up to 6 mg/dL (16.90 ± 
9.06 mg/dL; range: 2.50 to 32.30 mg/dL).
•	 Patient code 2: 9.38% of 32 serum Phe from 
108 to 1,534 days old were up to 6 mg/dL 
(1.89 ± 3.16 mg/dL; range: 0.01 to 15.25 
mg/dL). 
•	 Patient code 3: 61.11% of 18 serum Phe from 
61 to 1,617 days old were up to 6 mg/dL (6.46 
± 2.72 mg/dL; range: 0.70 to 9.70 mg/dL). 
•	 Patient code 4: 37.04% of 27 serum Phe from 
63 to 1,298 days old were up to 6 mg/dL (5.76 
± 4.67 mg/dL; range: 0.01 to 16.35 mg/dL).
These data were compared with the phenylalanine 
intake at 9 time points (Table 2). In five moments that 
the intake of phenylalanine dietary was low, biochemical 
control was normal in four patients (80%), but patient 
3 with low Phe intake at 17 months of age had serum 
Phe of 7.9 mg/dL, indicating inadequate control. In 
the four moments that the intake of phenylalanine 
was normal, biochemical control was adequate in only 
two patients (50%), and patient 1 at 11 months of 
age and patient 2 at 3 months of age had serum Phe 
concentrations above 6 mg/dL (7.5 and 6.2 mg/dL, 
respectively), indicating inadequate control. 
DISCUSSION
NBS/SE coverage was 78.93%, in 2007, 76.28% in 
2005 and 72% in 2003 (15-17). This number is indeed 
higher if we take into consideration that 11% of coverage 
done by the private healthcare system (according to 
data of National Agency of Supplementary Health) 
is not included in this coverage (16). Regardeless of 
this, efforts must be made to reach universal coverage. 
The rate of 10% of unscreened children is ethically 
unacceptable. 
The incidence of hyperphenylalaninemia was 
1/43,449; 20% of the suspected cases; similar to what 
was reported in a French program (25).The incidence 
of PKU was 1/8,690, halfway between most European 
(more than 1 in 10,0000) and Arabian countries (up to 
1 in 5,000) (1,2), and higher than in people of African 
ancestry (26). Although, the very low incidence seen in 
Finland (1 in 200,000) and Japan (1 in 125,000) was 
due to a pronounced negative founder effect in Finland 
and genetic drift in the founding of the Japanese island 
population; the high incidence of PKU in Turkey 
(1:2,600) was probably due to the high prevalence of 
consanguinity (2). There was one case of mild PKU 
(20% of the cases) and four cases of classic PKU (80% of 
the cases). These percentages are similar to those found 
in the neighboring Brazilian state of Bahia (27). 
The time blood collection in filter paper (PKUneo) 
from 2 to 30 days of age did not interfere with the 
Table 2. Follow up of subjects with phenylketonuria
Gender code Month of age Phe intake Recommended  Phe intake 
Serum Phe 
mg/dL Metabolic control 
F
1
5 29.09* 40 ± 10 2.5 Normal
11 23.49 30 ± 8 7.5 Above 
F
2
3 41.16 58 ± 18 6.2 Above 
8 29.49 32 ± 9 0.65 Below 
16 24.87 30 ± 8 1.70 Below 
M
3
6 26.21* 40 ± 10 3.1 Normal 
17 16.13* 30 ± 8 7.9 Above 
M
4
2 22.71* 58 ± 18 5.85 Normal 
3 21.26* 58 ± 18 3.65 Normal 
PKUneo: phenylalanine dosage in filter paper. Phe intake: phenylalanine intake mg/kg/weight/day.* Recommended phenylalanine intake (mg/kg/weight) less than a standard deviation (19). Metabolic 
control is defined normal when serum Phe is from 2 to 6 mg/dL (22).
Phenylketonuria in Sergipe
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establishment of the cutoff value. In a study with Cuban 
children (18), 9 showed PKUneo values somehow 
lower than ours (1.10 ± 0.85 mg/dL), suggesting that 
cutoff levels may have regional variability. A historical 
paper, using our enzymatic colorimetric process, 
analyzed 3,800 French children with a cutoff value of 
3.5 standard deviations above the mean (3 mg/dL). 
They recalled 15 children (recall rate of 0.39%) with 
one PKU case, 6.66% of children recalled (20). If we 
had used the cutoff of 3.5 standard deviations above 
the mean (4 mg/dL), we would have had a recall rate 
of 0.287% (125 children). By using the cutoff of 5.0 
mg/dL, our recall rate was 0.028% (almost eleven 
times lower than the recall rate of those authors), which 
represented just 12 children, with five PKU cases and 
one case of hyperphenylalaninemia. A lower recall rate 
prevents false-positives cases and causes less anxiety for 
the families. Although lower cutoffs than ours have 
been reported (19,20), our recall rate is near the lower 
inferior limit of those of different programs, ranging 
from 0.02% to 0.19% (21,22), suggesting no need for 
reduction in PKU cutoffs levels, as we have shown for 
congenital hypothyroidism (17). One suspected and 
one confirmed PKU subject died. Unfortunately, we 
do not know the causes of death in these subjects, but 
very seldom is PKU lethal (28). 
Analyses of biochemical control of our patients 
reveals that an appropriate phenylalanine intake is 
not a guarantee of normal biochemical control. This 
difficult metabolic control obtained despite low 
Phe diet suggests the need for new treatments, such 
as medications in liquid form (29), large neutral 
amino acid supplementation (30), or sapropiterin 
dihydrochloride (31) to improve compliance and 
prevent brain development sequels in cognitive 
function with neurological behavioral problems 
(32,33). Therefore, both the delayed beginning of 
treatment and inadequate metabolic control in the 
follow-up may cause impairment of the quality of life 
of our PKU individuals. It is interesting that even early-
treated PKU can impair the quality of life, in spite of 
universal and effective PKU NBS for more than 50 years 
(34). Therefore, we must continue to address factors 
that affect patient treatment outcomes, and not just 
celebrate the prevention of severe mental retardation 
(35), as obtained by our NBS program. 
In conclusion, our program does not provide 
universal coverage, but its cutoff is adequate for recalling 
and diagnosis. Nevertheless, the onset of treatment is 
often delayed, and the follow-up metabolic control is 
frequently inadequate. Improving NBS effectiveness is 
desirable to prevent suboptimal cognitive performance, 
and potential reversible brain lesions. Alternative 
treatment to the exclusive dietary control can be useful 
in this scenario.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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